Inhibition of lipase and inflammatory mediators by *Chlorella* lipid extracts for antiacne treatment

G. Sibi

Department of Biotechnology, Indian Academy Degree College, Centre for Research and Post Graduate Studies, Bengaluru, Karnataka, India

**Abstract**

Acne vulgaris is a chronic inflammatory disease, and its treatment is challenging due to the multifactorial etiology and emergence of antibiotic-resistant *Propionibacterium acnes* strains. This study was focused to reduce antibiotics usage and find an alternate therapeutic source for treating acne. Lipid extracts of six *Chlorella* species were tested for inhibition of lipase, reactive oxygen species (ROS) production, cytokine production using *P. acnes* (Microbial Type Culture Collection 1951). Lipase inhibitory assay was determined by dimercaprol Tributyrate - 5, 5'-dithiobis 2-nitrobenzoic acid method and ROS production assay was performed using nitro-blue tetrazolium test. The anti-inflammatory activity of algal lipid extracts was determined by *in vitro* screening method based on inhibition of pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) produced by human peripheral blood mononuclear cells. Minimum inhibitory concentration (MIC) values of lipid extracts were determined by microdilution method, and the fatty acid methyl esters (FAME) were analyzed by gas chromatography-mass spectroscopy. *Chlorella ellipsoidea* has the highest lipase inhibitory activity with 61.73% inhibition, followed by *Chlorella vulgaris* (60.31%) and *Chlorella protothecoides* (58.9%). Lipid extracts from *C. protothecoides* and *C. ellipsoidea* has significantly reduced the ROS production by 61.27% and 58.34% respectively. Inhibition of pro-inflammatory cytokines TNF-α showed the inhibition ranging from 58.39% to 78.67%. *C. vulgaris* has exhibited the MIC value of 10 µg/ml followed by *C. ellipsoidea*, *C. protothecoides* and *Chlorella pyrenoidosa* (20 µg/ml). FAME analysis detected 19 fatty acids of which 5 were saturated fatty acids, and 14 were unsaturated fatty acids ranging from C14 to C24. The results suggest that lipid extracts of *Chlorella* species has significant inhibitory activity on *P. acnes* by inhibiting lipase activity. Further, anti-inflammatory reaction caused by the pathogen could be reduced by the inhibiting the production of ROS and inflammatory mediators TNF-α and exposes new frontiers on the antiacne activities of *Chlorella* lipid extracts.

**Key words:** Antiacne, antiinflammatory, *Chlorella*, lipase inhibition, reactive oxygen species

**INTRODUCTION**

Acne is a chronic inflammatory disease characterized by seborrhea, the formation of open and closed comedones, erythematous papules, pustules and in more severe cases nodules, deep pustules and pseudocysts. It affects approximately 85% of the individuals aged between 12 and 24 years at some time. Excess sebum production, hyperkeratinization of the hair follicle, oxidative stress and the release of inflammatory mediators are the common pathways involved in acne development. Colonization of the skin by *Propionibacterium acnes* is one factor involved in the etiology of acne vulgaris. *P. acnes* is the dominant isolate from acne lesion, which is a Gram-positive...
anaerobe and has been implicated in inflammatory phase of acne.[7] It induces inflammation of sebaceous glands in human face, neck, chest or back.[8]

It is challenging to treat acne vulgaris due to the multifactorial etiology.[9] Triclosan, benzoyl peroxide, azelaic acid, retinoid, tetracycline, erythromycin, macrolide, levofloxacin and clindamycin are the most commonly prescribed antibiotics to treat acne vulgaris.[10-14] However, these antibiotics are associated with several side-effects when used for a long period.[15] Combination therapy with a topical retinoid and an antibiotic can normalize follicular epithelial desquamation and reduce bacterial proliferation.[16] Antimicrobial therapy for acne has also been complicated by the emergence of antibiotic-resistant strains of *P. acnes*.[17] The widespread and long-term use of antibiotics in the treatment of acne has resulted in the spread of resistant bacterial strains and treatment failure.[18, 19] The inevitable emergence of antibiotic-resistant strains of *P. acnes* has created some serious health care implication.[20] Therefore, there is a need to develop new medicines or therapies for acne treatment and this study was focused to reduce antibiotics usage and find an alternate therapeutic source for treating acne. In this regard, lipid extracts of *Chlorella* species were tested for inhibition of lipase and inflammatory mediators as novel therapeutic agents for effective acne therapy.

**MATERIALS AND METHODS**

**Chemicals and reagents**

Tetracycline hydrochloride, isopropyl methylphenol, dimercaprol tributyrate (BALB), 5, 5’-dithiobis 2-nitrobenzoic acid (DTNB) were purchased from Sigma Aldrich (Bengaluru), India and all other chemicals of highest purity grade were purchased from SD Fine Chemicals, Bengaluru. Brain heart infusion (BHI) broth was obtained from HiMedia Laboratories. For the quantification of cytokines, tumor necrosis factor alpha (TNF-α) ELISA kit was purchased from Sigma-Aldrich (Mumbai).

**Algal lipid extraction**

Six *Chlorella* species namely *Chlorella ellipsoidea*, *Chlorella emersonii*, *Chlorella protothecoides*, *Chlorella pyrenoidosa*, *Chlorella sorokiniana* and *Chlorella vulgaris* were used in this study. The algae were isolated from Bangalore freshwater habitats (13°04’N and 77°58’E), identified[21] and cultivated in Bold’s basal medium. Algal lipids were extracted according to the method of Folch *et al.*[22] Briefly, the cells were centrifuged at 10,000 rpm for 10 min and the pellet was homogenized with chloroform-methanol (2:1 v/v) solution. The sample was centrifuged and to the supernatant, 0.73% NaCl water was added to produce a final solvent system of 2:1:0.8 chloroform: Methanol: Water (v/v/v). The mixture was shaken for 5 min and centrifuged for 15 min at 2000 rpm to separate the phases. The lower organic phase was collected, and the chloroform-methanol solution was evaporated under a steam of nitrogen for further studies.

**Test organism**

*Propionibacterium acnes* (Microbial Type Culture Collection [MTCC] 1951) was procured from MTCC, India.

**Lipase inhibitory assay**

Crude lipase was prepared by centrifuging cell suspension of *P. acnes* (rabbit blood agar) at 900 ×g for 10 min at 4°C. The precipitate was diluted in phosphate buffer saline (PBS) (pH 6.8). The cells were homogenized and centrifuged at 5000 ×g for 1 min. The filtrate was collected and dialyzed for 6 days, followed by lyophilization of the crude extract.[23, 24]

Lipase inhibitory assay was determined by BALB-DTNB method described by Furukawa *et al.*[25] using tetracycline hydrochloride and isopropyl methylphenol as the positive controls.

**Reactive oxygen species production inhibition assay**

*Propionibacterium acnes* cultivated in BHI and glucose with and without algal extracts (100 µg/ml) for 72 h at 37°C in anaerobic conditions were used as stimulant for reactive oxygen species (ROS) activity. ROS production assay was performed using nitro-blue tetrazolium (NBT) test according to the method of Park *et al.*[26] Briefly, 500 µl of venous blood of healthy Sprague-Dawley (SD) rats, 50 µl of stimulants (*P. acnes* with and without algal extracts), positive control (polymorphonuclear leucocytes with zymosan) and negative control (culture media) were mixed and incubated at 25°C for 15 min. This was followed by the addition of 100 µl of NBT solution in 1 mg/ml of PBS and incubated at 37°C for 30 min and then again at 25°C for 20 min. Finally, smears were prepared and stained by Leishman’s stain for differential counting of formazan deposits in polymorphonuclear leucocytes.

**Cytokine production inhibition assay**

The anti-inflammatory activity of algal extracts was determined by *in vitro* screening method based on inhibition of pro-inflammatory cytokines (TNF-α) produced by human peripheral blood mononuclear cells (PBMC).[27] *P. acnes* was grown in 1% glucose BHI for 72 h at 37°C in an anaerobic atmosphere. The log phase bacterial culture was harvested, washed thrice in PBS (pH 7.2), and incubated at 80°C for 30 min to heat-kill the bacteria.

Isolation of PBMC was prepared from venous blood of healthy SD rats. Blood was diluted 1:2 with phosphate-buffered saline (pH 7.2), layered on Histopaque, washed thrice with PBS and resuspended in complete RPMI-1640 supplemented with 10% fetal calf serum (FCS). The cells were counted and resuspended at a concentration of 1 × 10⁶ cells/ml in RPMI supplemented with 10% FCS. Cell viability was determined using the tryphan blue dye exclusion test.
**Quantification of cytokines**

A 1-ml culture of PBMC (1 × 10^6 cells) was setup in 24 well tissue culture plates and stimulated with heat-killed *P. acnes* (1 × 10^6 cells/ml) in the presence or absence of algal extracts at a concentration of 40 µg/ml. Cultures were incubated at 37°C for 18 h in a humidified atmosphere containing 5% CO₂. Cultures without stimulants were set up as controls. The cultures were centrifuged to collect cell-free supernatant containing secreted cytokines and analyzed for TNF-α using sandwich ELISA (Sigma, India).

The ratio (%) of inhibition of the cytokine release was calculated using the following equation:

\[ \text{Degree of inhibition (%) = } 100 \times (1 - \frac{T}{C}) \]

T: Concentration of cytokines in culture supernatant with the test compound.

C: Concentration of cytokines in culture supernatant with the solvent.

**Anti-acne assay**

The antibacterial activity of algal lipid extract was determined by microdilution method in 96 well plates. Lipid extracts of 5, 10, 20, 40 and 80 µg/ml were used to determine the minimum inhibitory concentration (MIC) values. *P. acnes* was incubated in BHI medium for 48 h under anaerobic conditions and 100 µL of bacterial inoculum contained approximately 1 × 10^6 CFU/ml was inoculated into the wells. This was followed by incubation at 37°C for 72 h under anaerobic conditions in an anaerobic bag with gas pack and indicator tablets. All tests were performed in triplicates using clindamycin as a positive control.

**Fatty acid methyl ester preparation and analysis**

The fatty acid methyl esters (FAME) were converted from lipids and free fatty acids according to protocol of Lepage and Roy.[29] Algal cultures were centrifuged, and 0.1 g of pellet was homogenized with 1.5 ml of acetyl chloride and methanol (20:1, v/v) in reaction vessels. Subsequently, 1 ml of hexane was added to the mixture and heated to 100°C for 1 h for derivatization. The mixture was cooled, and 1 ml of distilled water was added and the organic phase was separated by centrifugation and dried with anhydrous sodium sulfate. The extracts were filtered and FAME was analyzed on gas chromatography-mass spectroscopy by following conditions described earlier.[29]

**RESULTS**

Lipase inhibitory assay using BALB-DTNB method revealed that *C. ellipsoidea* has the highest activity with 61.73% inhibition, followed by *C. vulgaris* (60.31%) and *C. protothecoides* (58.9%). Superoxide radical production by measuring polymorphonuclear leucocytes containing formazan deposit in the presence of the algal extract was done using NBT assay. The results showed that *Chlorella* extracts significantly reduced the ROS production with the inhibitory ratio of 61.27% and 58.34% by *C. protothecoides* and *C. ellipsoidea* respectively [Table 1]. Inhibition of pro-inflammatory cytokines (TNF-α) by the algal extracts were performed along with stimulant and positive control to determine the stimulatory role of *P. acnes*. Heat killed *P. acnes* have increased the production of TNF-α at 89.34 pg/ml, which was 19.8% higher than the positive control (71.58 pg/ml). Inhibitory effects of algal extracts on TNF-α showed the inhibition with 78.67% by *C. ellipsoidea*. Lipid extracts of *Chlorella* species were tested for *in vitro* anti acne activity by micro dilution method and the MIC was observed as 10 µg/ml for *C. vulgaris* and 20 µg/ml for *C. ellipsoidea*, *C. protothecoides* and *C. pyrenoidosa* [Table 2].

Fatty acid analysis of *Chlorella* extracts detected 19 fatty acids altogether [Table 3], including 5 saturated fatty acids (SFA) and 14 unsaturated fatty acids. The unsaturated fatty acids comprised of 8 mono-unsaturated fatty acids (MUFA), 6 polyunsaturated fatty acids (PUFAs). The SFA ranged from C14 to C18 and the unsaturated fatty acids were from C14 to C24. The most abundant fatty acids were pentadecyclic (C15:0), palmitic (C16:0), oleic (C18:1) and linoleic (C18:2) acids. All the species analyzed in this study presented considerably higher amounts of unsaturated fatty acids (73.6%). In *C. vulgaris*, the content of palmitic and linoleic acid were

**Table 1: Inhibitory activities of Chlorella lipid extracts on lipase, ROS and pro-inflammatory cytokines production**

| Organism     | Lipase inhibition (%) | ROS inhibition (%) | TNF-α inhibition (%) |
|--------------|-----------------------|--------------------|----------------------|
| *C. ellipsoidea* | 61.73±0.06           | 58.34±1.05        | 78.67±0.62          |
| *C. emersonii*   | 39.67±0.19           | 49.20±0.27        | 58.39±0.05          |
| *C. protothecoides* | 58.90±0.74     | 61.27±0.21        | 71.02±0.15          |
| *C. pyrenoidosa* | 47.16±1.37           | 55.09±0.54        | 69.17±1.94          |
| *C. sorokiniana* | 46.91±0.28           | 46.38±0.02        | 63.75±1.16          |
| *C. vulgaris*    | 60.31±0.10           | 57.95±0.10        | 73.46±1.00          |

| ROS: Reactive oxygen species, TNF-α: Tumor necrosis factor-alpha. P ≤ 0.05 |

**Table 2: Anti-acne activity of Chlorella lipid extracts**

| Organism     | MIC values (µg/ml) |
|--------------|--------------------|
| *C. ellipsoidea* | 20                 |
| *C. emersonii*   | 40                 |
| *C. protothecoides* | 20               |
| *C. pyrenoidosa* | 20                 |
| *C. sorokiniana* | ≥80                |
| *C. vulgaris*    | 10                 |
| Clindamycin     | 5                  |

| MIC: Minimum inhibitory concentration |
higher (11.31% and 8.29%) while oleic acid was higher in *C. protothecoides* (4.38%). Optimum fatty acid levels were observed with *C. ellipsoidea* while it exhibited the largest fatty acid profile as it contained 14 different fatty acids and the next diverse were *C. emersonii*, *C. pyrenoidosa* and *C. vulgaris* with 12 different fatty acids.

**DISCUSSION**

The major factors to cause acne vulgaris include follicular hyperkeratosis, sebum secretion, *P. acnes* and inflammation.[30] *P. acnes* produce enzymes such as lipases, proteases and hyaluronidases leading to subsequent inflammatory reactions in the surrounding dermis.[31] Formation of free fatty acids as a result of *P. acnes* lipases on sebaceous triglycerides induces severe inflammation.[32] One of the objectives of this study was to determine the lipase inhibition by algal extracts thereby reducing the pathogenicity of *P. acnes*. The use of BALB-DTNB method revealed that the lipase activity was inhibited up to 61.73% by *C. ellipsoidea*, followed by *C. vulgaris* and *C. protothecoides*. Lipase might play an important role in facilitating bacterial colonization in nutrient-limited environments such as the human skin. Compounds targeting acne should inhibit *P. acnes* lipase activity[28] and the present findings suggest that algal inhibitory action may contribute to the eradication of *P. acnes* colonization on human skin through lipase inhibition and at the same time it could be used as a nonantibiotic source for skin care.

*Propionibacterium acnes* can evoke local inflammation by producing neutrophil chemotactic factors and the attracted neutrophils release inflammatory mediators such as ROS.[33] Though ROS perform a useful function in the skin barrier against acne microbes[34] excess formation affects skin condition by activating neutrophil infiltration leads to irritation and disruption of the integrity of the follicular epithelium and are responsible for the progression of inflammatory acne. Removal of the ROS can significantly reduce cell damage that may occur during acne inflammation.[35] Inhibition of ROS production using the lipid extracts revealed that *Chlorella* species has significant inhibitory activity thereby reducing inflammatory cell damage.

In addition, free fatty acids released from lipase activity and ROS can also act as second messengers in the induction of several biological responses like the generation of cytokines.[36] Inflammation acts as a central executor in the pathogenesis of acne where TNF-α and interleukin-1β are the cytokines that act as signaling molecules for immune cells and co-ordinate the inflammatory responses.[37] In this study, the stimulatory role of *P. acnes* on pro-inflammatory cytokine (TNF-α) production was demonstrated followed by inhibitory action by the algal extracts where 78.67% inhibition was observed. The results suggest that the anti-inflammatory activity of the microalgal extract may be used in down-regulation of the inflammatory mediator's production by *P. acnes* in acne vulgaris. Antiacne

### Table 3: FAME analysis of *Chlorella* lipid extracts (%)

| Fatty acids | *C. ellipsoidea* | *C. emersonii* | *C. protothecoides* | *C. pyrenoidosa* | *C. sorokiniana* | *C. vulgaris* |
|------------|-----------------|----------------|---------------------|-----------------|-----------------|-------------|
| SFAs       |                 |                |                     |                 |                 |             |
| C14:0      | 0.17            | 0.09           | ND                  | 0.11            | 0.08            | 0.10        |
| C15:0      | 0.48            | 0.01           | 0.51                | 0.09            | 0.22            | 0.37        |
| C16:0      | 4.21            | 7.02           | 8.37                | 8.04            | 3.96            | 11.31       |
| C17:0      | ND              | ND             | ND                  | ND              | ND              | 0.06        |
| C18:0      | 0.07            | 0.09           | ND                  | 0.17            | ND              | 0.26        |
| MUFA       |                 |                |                     |                 |                 |             |
| C14:1      | ND              | 0.12           | 0.26                | 0.05            | 0.17            | ND          |
| C15:1      | ND              | 0.06           | ND                  | ND              | ND              | ND          |
| C16:1      | 0.27            | 0.05           | 0.14                | ND              | 0.11            | 0.16        |
| C17:1      | 0.03            | ND             | 0.14                | 0.11            | ND              | ND          |
| C18:1      | 2.37            | 2.09           | 4.38                | 1.84            | 0.98            | 3.07        |
| C20:1      | 1.05            | ND             | 0.96                | ND              | 1.47            | 0.63        |
| C22:1      | ND              | 0.05           | 0.33                | ND              | ND              | ND          |
| C24:1      | 1.67            | 1.25           | ND                  | 0.37            | 0.66            | 0.39        |
| PUFA       |                 |                |                     |                 |                 |             |
| C14:2      | 0.02            | ND             | 0.05                | ND              | ND              | 0.09        |
| C15:3      | ND              | ND             | ND                  | 0.08            | 0.03            | ND          |
| C16:2      | 0.10            | ND             | ND                  | 0.09            | ND              | ND          |
| C17:2      | 0.16            | 0.08           | ND                  | ND              | ND              | ND          |
| C18:2      | 4.37            | 6.24           | 7.35                | 5.47            | 2.06            | 8.29        |
| C23:6      | 0.20            | ND             | ND                  | 0.45            | 0.44            | 0.26        |

*ND: Not detected, FAME: Fatty acid methyl esters, SFA: Saturated fatty acid, MUFA: Mono unsaturated fatty acid, PUFA: Poly unsaturated fatty acid*
compounds from marine algae were reported in earlier studies and in this study, antiacne activity of lipid extracts from fresh water Chlorella species were determined. It was hypothesized that lipids kill microorganisms by disruption of the cellular membrane. Antimicrobial susceptibility of P. acnes to microalgal extract was performed using micro dilution method in which the MIC values were from 10 to 40 µg/ml except C. sorokiniana (280 µg/ml). In the previous report, MIC of glycolipid extract of macroalges against P. acnes was observed at 50 µg/ml. Clindamycin and erythromycin are the most common antibiotics used against P. acnes hence clindamycin was used as positive control.

The data about the detailed composition of Chlorella lipids are available but no reports exist in literature about anti acne activity of their lipids. In this work, the six Chlorella species lipids were investigated as a natural source of functional bio-actives to control acne. In addition, inhibitors of bacterial lipase, ROS and inflammatory mediators from Chlorella lipids were also studied. For this, FAME were prepared and analyzed. MUFA and PUFA were the main FAME detected in the profile among various Chlorella species. Regarding the size of the carbon chain, the species displayed a FAME profile ranging from C14 to C23. The presence of oleic and linoleic acid in Chlorella species was reported earlier.

**CONCLUSION**

This study analyzed whether algal lipid extract could reduce the pathogenicity of P. acnes with regard to acne development. Further, anti-inflammatory reaction caused by the pathogen could be reduced by the inhibiting the production of ROS and inflammatory mediators (TNF-α) which exposes new frontiers on the anti-acne activities of Chlorella lipid extracts.

**REFERENCES**

1. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Text Book of Dermatology. 8th ed., Vol. 1. United Kingdom: Wiley-Blackwell Ltd.; 2010. p. 42, 17.
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003;49 3 Suppl: S200-10.
3. Katzman M, Logan AC. Acne vulgaris: Nutritional factors may be influencing psychological sequelae. Med Hypotheses 2007;69:1080-4.
4. Nouri K, Ballard C. Laser therapy for acne. Clin Dermatol 2006;24:26-32.
5. Bojar RA, Holland KT. Acne and Propionibacterium acnes. Clin Dermatol 2004;22:375-9.
6. Nishijima S, Kurokawa I, Katoh N, Watanabe K. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000;27:318-23.
7. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-63.
8. Park J, Lee J, Jung E, Park Y, Kim K, Park B, et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 2004;496:189-95.
9. Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol 2012;13:357-64.
10. Golnick H, Cunliffe W, Werson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: A report from a Global Alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49 1 Suppl: S1-37.
11. Ravenscroft J. Evidence based update on the management of acne. Arch Dis Child Educ Pract Ed 2005;90:EP98-101.
12. Han S, Lee K, Yeo J, Baek H, Park K. Antibacterial and anti-inflammatory effects of honeybee (Apis mellifera) venom against acne-inducing bacteria. J Med Plants Res 2010;4:459-64.
13. Kawada A, Aragane Y, Tezuka T. Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: An open study. Dermatology 2002;204:301-2.
14. Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc 2001;34:29-40.
15. Kim YJ, Oh TH, Kim BJ, Kim SS, Lee NH, Hyun CG. Chemical composition and anti-inflammatory effects of essential oil from Farfugium japonicum flower. J Oleo Sci 2008;57:623-8.
16. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001;15 Suppl 3:51-5.
17. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010;74:417-33.
18. Moon SH, Roh HS, Kim YH, Kim JE, Ko JY, Ro YS. Antibiotic resistance of microbial strains isolated from Korean acne patients. J Dermatol 2012;39:833-7.
19. Song M, Seo SH, Ko HC, Oh CK, Kwon KS, Chang CL, et al. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J Dermatol 2011;38:667-73.
20. Andersen RA. Algal Culturing Techniques. 1st ed. California, USA: Elsevier Academic Press; 2003. p. 578.
21. Round FE. The Biology of the Algae. 2nd ed. London: Edward Arnold Publishers; 1973.
22. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
23. Batubara IT, Mitsuanga H, Ohashi H. Screening anti-acne potency of Indonesian medicinal plants: Antibacterial, lipase inhibition, and antioxidant activities. J Wood Sci 2009;55:230-5.
24. Muddathir AM, Mitsuanga T. Evaluation of anti-acne activity of selected Sudanese medicinal plants. J Wood Sci 2013;59:73-9.
25. Furukawa I, Kurooka S, Arisue K, Kohda K, Hayashi C. Assays of serum lipase by the “BALB-DTNB method” mechanized for use with discrete and continuous-flow analyzers. Clin Chem 1982;28:110-3.
26. Park BH, Fikrig SM, Smithwick EM. Infection and nitroblue-tetrazolium reduction by neutrophils. A diagnostic acid. Lancet 1968;2:532-4.
27. Jain A, Basal E. Inhibition of Propionibacterium acnes-induced mediators of inflammation by Indian herbs. Phytomedicine 2003;10:34-8.
28. Lepage G, Roy CC. Improved recovery of fatty acid through direct transesterification without prior extraction or purification. J Lipid Res 1984;25:1391-6.
29. Sibi G, Anuraag TS, Bafila G. Copper stress on cellular contents and fatty acid profiles in Chlorella species. Online J Biol Sci 2014:14:209-17.
30. Knor T. The pathogenesis of acne. Acta Dermatovenerol Croat 2005;13:44-9.
31. Hoeffler U. Enzymatic and hemolytic properties of Propionibacterium acnes and related bacteria. J Clin Microbiol 1977;6:555-8.
32. Higaki S. Lipase inhibitors for the treatment of acne. J Mol Catal 2003;22:377-84.
33. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997;336:1156-62.
34. Boh EE. Role of reactive oxygen species in dermatologic diseases. Clin Dermatol 1996;14:343-52.
35. Chen Q, Koga T, Uchi H, Hara H, Terao H, Moroi Y, et al. Propionibacterium acnes-induced IL-8 production may be mediated by NF-kappaB activation in human monocytes. J Dermatol Sci 2002;29:97-103.
36. Harrison D, Harrison E. Natural therapeutic composition for the treatment of wounds and Sores. Cipopatent, 2392544; 2003.
37. Krakauer T. Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB. Curr Drug Targets Inflamm Allergy 2004;3:317-24.
38. Kamei Y, Sueyoshi M, Hayashi K, Terada R, Nozaki H. The novel anti-Propionibacterium acnes compound, Sargafuran, found in the marine brown alga Sargassum macrocarpum. J Antibiot (Tokyo) 2009;62:259-63.
39. Choi JS, Bae HJ, Kim SJ, Choi IS. In vitro antibacterial and anti-inflammatory properties of seaweed extracts against acne inducing bacteria, Propionibacterium acnes. J Environ Biol 2011;32:313-8.
40. Lee JH, Eom SH, Lee EH, Jung YJ, Kim HJ, Jo MR, et al. In vitro antibacterial and synergistic effect of phlorotannins isolated from edible brown seaweed Eisenia bicyclis against acne-related bacteria. Algae 2014;29:47-55.
41. Lampe MF, Ballweber LM, Isaacs CE, Patton DL, Stamm WE. Killing of Chlamydia trachomatis by novel antimicrobial lipids adapted from compounds in human breast milk. Antimicrob Agents Chemother 1998;42:1239-44.
42. Treyvaud Amiguet V, Jewell LE, Mao H, Sharma M, Hudson JB, Durst T, et al. Antibacterial properties of a glycolipid-rich extract and active principle from Nunavik collections of the macroalgae Fucus evanesceus C. Agardh (Fucaceae). Can J Microbiol 2011;57:745-9.
43. Otles S, Pire R. Fatty acid composition of Chlorophyll and Spirulina microalgae species. J AOAC Int 2001;84:1708-14.